170 related articles for article (PubMed ID: 15005638)
1. Clinical pharmacokinetics of quinupristin/dalfopristin.
Bearden DT
Clin Pharmacokinet; 2004; 43(4):239-52. PubMed ID: 15005638
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans.
Bergeron M; Montay G
J Antimicrob Chemother; 1997 May; 39 Suppl A():129-38. PubMed ID: 9511077
[TBL] [Abstract][Full Text] [Related]
3. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
Lamb HM; Figgitt DP; Faulds D
Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients.
Johnson CA; Taylor CA; Zimmerman SW; Bridson WE; Chevalier P; Pasquier O; Baybutt RI
Antimicrob Agents Chemother; 1999 Jan; 43(1):152-6. PubMed ID: 9869581
[TBL] [Abstract][Full Text] [Related]
5. Quinupristin-dalfopristin (RP 59500): an injectable streptogramin combination.
Griswold MW; Lomaestro BM; Briceland LL
Am J Health Syst Pharm; 1996 Sep; 53(17):2045-53. PubMed ID: 8870891
[TBL] [Abstract][Full Text] [Related]
6. Multiple-dose pharmacokinetics and safety of two regimens of quinupristin/dalfopristin (Synercid) in healthy volunteers.
Chevalier P; Rey J; Pasquier O; Rouzier-Panis R; Harding N; Montay G
J Clin Pharmacol; 2001 Apr; 41(4):404-14. PubMed ID: 11304897
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid).
Ling TK; Fung KS; Cheng AF
Chemotherapy; 2001; 47(4):243-9. PubMed ID: 11399860
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of quinupristin/ dalfopristin in patients with severe chronic renal insufficiency.
Chevalier P; Rey J; Pasquier O; Leclerc V; Baguet JC; Meyrier A; Harding N; Montay G
Clin Pharmacokinet; 2000 Jul; 39(1):77-84. PubMed ID: 10926351
[TBL] [Abstract][Full Text] [Related]
9. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations.
Aeschlimann JR; Zervos MJ; Rybak MJ
Antimicrob Agents Chemother; 1998 Oct; 42(10):2710-7. PubMed ID: 9756782
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous high-performance liquid chromatographic determination of quinupristin, dalfopristin and their main metabolites in human plasma.
Le Liboux A; Pasquier O; Montay G
J Chromatogr B Biomed Sci Appl; 1998 Apr; 708(1-2):161-8. PubMed ID: 9653958
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of quinupristin/dalfopristin: administration guidelines.
Rubinstein E; Prokocimer P; Talbot GH
J Antimicrob Chemother; 1999 Sep; 44 Suppl A():37-46. PubMed ID: 10511396
[TBL] [Abstract][Full Text] [Related]
12. Quinupristin-dalfopristin: an overview.
Delgado G; Neuhauser MM; Bearden DT; Danziger LH
Pharmacotherapy; 2000 Dec; 20(12):1469-85. PubMed ID: 11130220
[TBL] [Abstract][Full Text] [Related]
13. Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): a report of fifteen cases.
Dever LL; Smith SM; Dejesus D; Masurekar M; Patel D; Kaminski ZC; Johanson WG
Microb Drug Resist; 1996; 2(4):407-13. PubMed ID: 9158811
[TBL] [Abstract][Full Text] [Related]
14. Quinupristin/dalfopristin attenuates the inflammatory response and reduces the concentration of neuron-specific enolase in the cerebrospinal fluid of rabbits with experimental Streptococcus pneumoniae meningitis.
Trostdorf F; Reinert RR; Schmidt H; Nichterlein T; Stuertz K; Schmitz-Salue M; Sadowski I; Brück W; Nau R
J Antimicrob Chemother; 1999 Jan; 43(1):87-94. PubMed ID: 10381105
[TBL] [Abstract][Full Text] [Related]
15. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
Baudoux P; Lemaire S; Denis O; Tulkens PM; Van Bambeke F; Glupczynski Y
J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of quinupristin/dalfopristin against gram-positive bacteria Haemophilus influenzae and Branhamella catarrhalis in Taiwan.
Wang FD; Lin ML; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jun; 63(6):433-9. PubMed ID: 10925532
[TBL] [Abstract][Full Text] [Related]
17. Subinhibitory quinupristin/dalfopristin attenuates virulence of Staphylococcus aureus.
Koszczol C; Bernardo K; Krönke M; Krut O
J Antimicrob Chemother; 2006 Sep; 58(3):564-74. PubMed ID: 16895938
[TBL] [Abstract][Full Text] [Related]
18. Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience.
Low DE
Microb Drug Resist; 1995; 1(3):223-34. PubMed ID: 9158779
[TBL] [Abstract][Full Text] [Related]
19. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.
Fagon J; Patrick H; Haas DW; Torres A; Gibert C; Cheadle WG; Falcone RE; Anholm JD; Paganin F; Fabian TC; Lilienthal F
Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):753-62. PubMed ID: 10712318
[TBL] [Abstract][Full Text] [Related]
20. Use of streptogramin growth promoters in poultry and isolation of streptogramin-resistant Enterococcus faecium from humans.
Kieke AL; Borchardt MA; Kieke BA; Spencer SK; Vandermause MF; Smith KE; Jawahir SL; Belongia EA;
J Infect Dis; 2006 Nov; 194(9):1200-8. PubMed ID: 17041845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
